LEILA COLSON: Open Payments
NPI 1841955861 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,254 in 108 payments from 15 companies in 2025. Trend: 2023 $1,084 · 2024 $2,830 · 2025 $2,254
Food & beverage: $2,254
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 46 | $761 |
| AstraZeneca Pharmaceuticals LP | 21 | $514 |
| Aimmune Therapeutics, Inc. | 8 | $242 |
| Novo Nordisk Inc | 8 | $194 |
| PFIZER INC. | 5 | $115 |
| GlaxoSmithKline, LLC. | 5 | $108 |
| Amgen Inc. | 4 | $100 |
| Ascendis Pharma Endocrinology Inc | 2 | $53 |
| Exact Sciences Corporation | 2 | $41 |
| Baxter Healthcare | 1 | $25 |
Products named: VRAYLAR, BREZTRI, QULIPTA, FARXIGA, ZENPEP, UBRELVY, OTEZLA, VYNDAMAX.
Industry payments across CT — which companies pay providers there.
